Posted by Michael Wonder on 14 Jun 2024
FDA approves blinatumomab as consolidation for CD19 positive Philadelphia chromosome negative B-cell precursor acute lymphoblastic leukaemia
14 June 2024 - Today, the FDA approved blinatumomab (Blincyto, Amgen) for adult and paediatric patients one month and older with CD19 positive Philadelphia chromosome negative B-cell precursor acute lymphoblastic leukaemia in the consolidation phase of multiphase chemotherapy.
Efficacy was evaluated in Study E1910, a randomised, controlled trial in adult patients with newly diagnosed Philadelphia chromosome negative B cell precursor acute lymphoblastic leukaemia.
